Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 79

Sort by

Sort Order Select

Journal Articles

CD8 + T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

Francesco Mazziotta, Luca Biavati, Joseph Rimando, Sergio Rutella, Nicholas Borcherding, Sonali Parbhoo, Rupkatha Mukhopadhyay, Sayan Chowdhury, Hanna A. Knaus, Peter Valent, Hubert Hackl, Ivan M. Borrello, Bruce R. Blazar, Katerina Hatzi, Ivana Gojo, Leo Luznik

Blood (2024) 144 (11): 1168–1182.

https://doi.org/10.1182/blood.2023021680

Published: 2024

Includes: Supplemental data

Journal Articles

Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study

Jonathan Allen Webster, Marlise R. Luskin, Joseph Rimando, Amanda Blackford, Amer M. Zeidan, Elad Sharon, Howard Streicher, Daniel J. DeAngelo, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 966.

https://doi.org/10.1182/blood-2023-191109

Published: 2023

Journal Articles

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

Joseph Rimando, Francesco Mazziotta, Alison Gareau, Maria Bettinotti, Jonathan Allen Webster, Syed Abbas Ali, Philip Imus, Mario Victor Lemas, Amy E. DeZern, Mark J. Levis, Marianna Zahurak, Ravi Varadhan, Richard F. Ambinder, Carol Huff, Ivana Gojo, Richard J. Jones, Ivan M. Borrello, Leo Luznik

Blood (2023) 142 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2023-179394

Published: 2023

Journal Articles

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

Jonathan Allen Webster, Richard J. Jones, Amanda Blackford, Audra Shedeck, Richard F. Ambinder, Lode J. Swinnen, Nina Wagner-Johnston, Ephraim Joseph Fuchs, Javier Bolanos-Meade, Philip Imus, Challice L. Bonifant, Heather Jill Symons, Tania Jain, Gabrielle T. Prince, Mark J. Levis, Leo Luznik, Ivana Gojo

Blood (2023) 142 (Supplement 1): 3582.

https://doi.org/10.1182/blood-2023-191047

Published: 2023

Journal Articles

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R. Wilson, Marina Konopleva, Arthur E. Frankel, Vikas Gupta, Ruben Mesa, Matthew Ulrickson, Edward Gorak, Sumeet Bhatia, Tulin Budak-Alpdogan, James Mason, Maria Teresa Garcia-Romero, Norma Lopez-Santiago, Gabriela Cesarman-Maus, Pankit Vachhani, Sangmin Lee, Vijaya Raj Bhatt, William Blum, Roland B. Walter, Dale Bixby, Ivana Gojo, Madeleine Duvic, Raajit K. Rampal, Marcos de Lima, James Foran, Amir T. Fathi, Aric Cameron Hall, Meagan A. Jacoby, Jeffrey Lancet, Gabriel Mannis, Anthony S. Stein, Alice Mims, David Rizzieri, Rebecca Olin, Alexander Perl, Gary Schiller, Paul Shami, Richard M. Stone, Stephen Strickland, Matthew J. Wieduwilt, Naval Daver, Farhad Ravandi, Sumithira Vasu, Monica Guzman, Gail J. Roboz, Joseph Khoury, Muzaffar Qazilbash, Phyu P. Aung, Branko Cuglievan, Yazan Madanat, Mohamed A. Kharfan-Dabaja, Anna Pawlowska, Justin Taylor, Martin Tallman, Prajwal Dhakal, Andrew A. Lane

Blood (2023) 141 (6): 567–578.

https://doi.org/10.1182/blood.2022017865

Published: 2023

Journal Articles

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Sergiu Pasca, Saurav D. Haldar, Alexander J. Ambinder, Jonathan Webster, Tania Jain, William Brian Dalton, Gabrielle T. Prince, Gabriel Ghiaur, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Cory Schulz, Kristin Stokvis, Mark J. Levis, Richard J. Jones, Lukasz P. Gondek

Blood (2022) 140 (Supplement 1): 10629–10631.

https://doi.org/10.1182/blood-2022-169148

Published: 2022

Journal Articles

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Blood (2022) 140 (Supplement 1): 4813–4815.

https://doi.org/10.1182/blood-2022-171038

Published: 2022

Journal Articles

Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Francesco Mazziotta, Luca Biavati, Sonali Parbhoo, Sayan Chowdhury, Joseph Rimando, Ivan M. Borrello, Katerina Hatzi, Bruce R. Blazar, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 9132–9133.

https://doi.org/10.1182/blood-2022-167107

Published: 2022

Journal Articles

Phase II Study of Tagraxofusp in Newly Diagnosed Secondary Acute Myeloid Leukemia (S-AML) after Previous Exposure to Hypomethylating Agents (TAGALONG Study)

Steven D. Green, Brian Parkin, Catherine Lai, Ivana Gojo, Matthew C. Foster, Joshua F. Zeidner

Blood (2022) 140 (Supplement 1): 11749–11750.

https://doi.org/10.1182/blood-2022-170738

Published: 2022

Journal Articles

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

Matthew Scarlotta, Jonathan Webster, Matthew Newman, Cory Schulz, Kristin Stokvis, Alexander J. Ambinder, Tania Jain, William Brian Dalton, Lukasz P. Gondek, Gabrielle T. Prince, Gabriel Ghiaur, Christopher S. Hourigan, Amy E. DeZern, Ivana Gojo, Jonathan Allen Webster, Mark J. Levis

Blood (2022) 140 (Supplement 1): 11747–11748.

https://doi.org/10.1182/blood-2022-160300

Published: 2022

Journal Articles

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Joseph Rimando, Leslie Cope, Karen McKinnon, Benjamin G. Vincent, Sergio Rutella, Joshua F. Zeidner, Jonathan S. Serody, Ivana Gojo, Leo Luznik

Blood (2022) 140 (Supplement 1): 6314–6315.

https://doi.org/10.1182/blood-2022-165458

Published: 2022

Journal Articles

Bone Marrow GZMK + IL7R + Progenitor-Exhausted CD8 + T Cells Correlate with Sustained Clinical Remission in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Francesco Mazziotta, Luca Biavati, Rupkatha Mukhopadhyay, Hanna A. Knaus, Ivan M. Borrello, Ivana Gojo, Leo Luznik

Blood (2021) 138 (Supplement 1): 521.

https://doi.org/10.1182/blood-2021-149150

Published: 2021

Journal Articles

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Blood (2021) 138 (Supplement 1): 1846.

https://doi.org/10.1182/blood-2021-153750

Published: 2021

Journal Articles

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Sergio Rutella, Jayakumar Vadakekolathu, Francesco Mazziotta, Stephen Reeder, Tung On Yau, Rupkatha Mukhopadhyay, Heidi Altmann, Michael Kramer, Hanna A. Knaus, Joshua F. Zeidner, Vedran Radojcic, Andrea Arruda, Mark D. Minden, Sarah K Tasian, Martin Bornhäuser, Ivana Gojo, Leo Luznik

Blood (2021) 138 (Supplement 1): 223.

https://doi.org/10.1182/blood-2021-145854

Published: 2021

Journal Articles

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Nicholas P. Tschernia, MD, Vaibhav Kumar, MBBS,MS, Dominic T. Moore, MPH, MS, Benjamin G. Vincent, MD, Callie C. Coombs, MD, Hendrik Van Deventer, MD, Matthew C. Foster, MD, Amy E. DeZern, MD, Leo Luznik, MD, Marcie L. Riches, MDMS, Jonathan S. Serody, MD, Ivana Gojo, MD, Joshua F. Zeidner, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-138786

Published: 2020

Journal Articles

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141294

Published: 2020

Journal Articles

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Blood (2020) 136 (Supplement 1): 42–44.

https://doi.org/10.1182/blood-2020-141264

Published: 2020

Journal Articles

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Sarah E. Church, PhD, Michael P. Rettig, PhD, Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Farhad Ravandi, MBBS, Antonio Curti, MDPhD, Max S. Topp, MD, John Muth, MS, Patrick Kaminker, PhD, Bob Lowenberg, MDPhD, Ivana Gojo, MD, Leo Luznik, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MDPhD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2020-134921

Published: 2020

Journal Articles

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-136919

Published: 2020

Journal Articles

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Heidi Altmann, PhD, Sarah E. Church, PhD, Hanna A Knaus, MD, Mark D. Minden, Jan K Davidson-Moncada, MDPhD, Sarah K Tasian, MD, Martin Bornhäuser, MD, Ivana Gojo, MD, Leo Luznik, MD, Sergio Rutella, MDPhDFRCPath

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-134779

Published: 2020

NARROW

CD8 + T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia

Blinatumomab in Combination with Immune Checkpoint Inhibitors (ICIs) of PD-1 and CTLA-4 in Adult Patients with Relapsed/Refractory (R/R) CD19 Positive B-Cell Acute Lymphoblastic Leukemia (ALL): Results of a Phase I Study

A Phase I Trial of Activated Donor-Derived Marrow Infiltrating Lymphocytes to Treat Relapsed Hematologic Malignancies after Allogeneic Transplantation with Post-Transplantation Cyclophosphamide As Graft-Versus-Host Disease Prophylaxis

A Phase IB/II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or Marrow Transplant (alloBMT) Remission Maintenance

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need

Outcomes of Patients with TP53 -Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Different Subsets of Exhausted and Senescent-like T Cells Correlate with Response and Survival in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Phase II Study of Tagraxofusp in Newly Diagnosed Secondary Acute Myeloid Leukemia (S-AML) after Previous Exposure to Hypomethylating Agents (TAGALONG Study)

Gemtuzumab Ozogamicin for Cytoreduction in Hyperleukocytosis

The Composition of Acute Myeloid Leukemia Cell Differentiation States Predicts Response to Immune Checkpoint Blockade

Bone Marrow GZMK + IL7R + Progenitor-Exhausted CD8 + T Cells Correlate with Sustained Clinical Remission in Patients with Acute Myeloid Leukemia (AML) Undergoing Chemotherapy

Nonmyeloablative Allogeneic Transplantation in First Remission for Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Outcomes By Receipt of Pre-Transplant Blinatumomab

Transcriptomic Features of Immune Exhaustion and Senescence Predict Outcomes and Define Checkpoint Blockade-Unresponsive Microenvironments in Acute Myeloid Leukemia

Safety and Efficacy of Pembrolizumab Prior to Allogeneic Stem Cell Transplant in Patients with Acute Myeloid Leukemia

Allogeneic Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia with Post-Transplantation Cyclophosphamide: Assessing the Importance of Conditioning Regimen, Donor Choice, and Tyrosine Kinase Inhibitor Use

Reduced-Intensity Induction with Dasatinib Vs. Hypercvad + 2 nd Generation TKIs with MRD-Guided Follow-up Therapy Leads to Comparable Rates of MRD-Negative Remission While Reducing Transfusions and Neutropenia in Ph+ ALL

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

An Immune Senescence and Exhaustion-Related RNA Profile Predicts Clinical Outcomes in Acute Myeloid Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only